enteric-coated naproxen

Phase 3

OOttawa Hospital Research Institute

enteric-coated naproxen is one of 14 therapeutic programs targeting Cellulitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

CellulitisNot yet recruiting

CellulitisPhase 3

Not yet recruiting

Competition

Competitive Landscape

17 competitors in Cellulitis

#DrugCompanyPhaseTrials

Acanya

Pfizer

Approved

1 2

Avelox

Bayer

Approved

—3

Cubicin

BBaxter Healthcare Corporation

Approved

1 4

Vancocin

HHikma Pharmaceuticals LLC

Approved

1 5

Levaquin

WWim Janssens

Approved

—6

Ancef

BBaxter Healthcare Corporation

Flucloxacillin

3 8

Phenoxymethylpenicillin

UUniversity of Aarhus

Approved

1 9

Keflex

Eli Lilly

Preclinical

3 10

enteric-coated naproxen

OOttawa Hospital Research Institute

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Not yet recruiting

Cellulitis

NCT07665476

Clinical

Trials by Indication[1]

Cellulitis1 trial

Naproxen Versus Placebo as Adjunct Treatment of Cellulitis: A Randomized Controlled Trial

Not yet recruiting·OOttawa Hospital Research Institute·Phase 3·NCT07665476·884 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for enteric-coated naproxen. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for enteric-coated naproxen. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ottawa Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: OOttawa Hospital Research Institute

enteric-coated naproxen

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Cellulitis1 trial

References

Drug Info

Quick Facts

Related News